Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Reply to: Cisplatin-induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib

Nature Medicine volume 18, pages 1172–1174 (2012)Cite this article

Subjects

Maiani et al. reply:

Kerr et al.1 report that imatinib does not protect primordial oocytes from cisplatin-induced apoptosis. This stands in contrast with the results of a recent report from our group in Nature Medicine2. Furthermore, Kerr et al.1 claim that imatinib causes oocyte death, possibly by blocking the tyrosine kinase activity of the stem cell factor receptor c-Kit, which is considered crucial for oocyte survival3. They state that they find no support for a new use for imatinib aimed at preserving the follicle reserve during cancer therapy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Pharmacological inhibition of c-Abl protects reserve follicle oocytes and impairs gH2AX phosphorylation induced by DNA damage.

References

  1. Kerr, J.B. et al. Nat. Med. 18, 1170–1172 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Gonfloni, S. et al. Nat. Med. 15, 1179–1185 (2009).

    Article  CAS  PubMed  Google Scholar 

  3. Carlsson, I.B. et al. Reproduction 131, 641–649 (2006).

    Article  CAS  PubMed  Google Scholar 

  4. Schultheis, B., Nijmeijer, B.A., Yin, H., Gosden, R.G. & Melo, J.V. Leuk. Res. 36, 271–274 (2012).

    Article  CAS  PubMed  Google Scholar 

  5. Adrián, F.J. et al. Nat. Chem. Biol. 2, 95–102 (2006).

    Article  PubMed  Google Scholar 

  6. Fabbro, D. et al. Biochim. Biophys. Acta 1804, 454–462 (2010).

    Article  CAS  PubMed  Google Scholar 

  7. Suh, E.K. et al. Nature 444, 624–628 (2006).

    Article  CAS  Google Scholar 

  8. Wang, X. et al. Cell Death Differ. 18, 5–15 (2011).

    Article  PubMed  Google Scholar 

  9. Jiang, Z. et al. Mol. Cancer 10, 88 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Ulrich, H.D. & Walden, H. Nat. Rev. Mol. Cell Biol. 11, 479–489 (2010).

    Article  CAS  PubMed  Google Scholar 

  11. Yuan, J. & Chen, J. J. Biol. Chem. 285, 1097–1104 (2010).

    Article  CAS  PubMed  Google Scholar 

  12. Maiani, E., Diederich, M. & Gonfloni, S. Biochem. Pharmacol. 82, 1269–1276 (2011).

    Article  CAS  PubMed  Google Scholar 

  13. Cairns, L.A. et al. Blood 102, 3954–3962 (2003).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank G. Mazzeo for support. We are indebted to S. Filoni for his valuable guidance. We thank S. Dolci (Department of Biomedicine and Prevention, University of Rome “Tor Vergata”) for transgenic c-Kit mice, A.M. Lena (Department of Experimental Medicine and Biochemical Sciences, University of Rome “Tor Vergata”) for the SaosTAp63alfa cell line and F. Maina and C. Gargioli for suggestions. We acknowledge support from Associazione Italiana per la Ricerca sul Cancro to S.G. and G.C. Research in M.D.'s lab is supported by the “Recherche Cancer et Sang,” the “Recherches Scientifiques Luxembourg” association, the “Een Haerz fir kriibskrank Kanner” association, the Action Lions “Vaincre le Cancer” association and Televie Luxembourg.

Author information

Author notes

  1. Emiliano Maiani and Claudia Di Bartolomeo: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Biology, University of Rome, “Tor Vergata,”, Rome, Italy

    Emiliano Maiani, Claudia Di Bartolomeo, Stefano M Cannata, Sergio Bernardini, Maurizio Mattei, Gianni Cesareni & Stefania Gonfloni

  2. Department of Biomedicine and Prevention, University of Rome, “Tor Vergata,”, Rome, Italy

    Francesca G Klinger & Massimo De Felici

  3. Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Fondation de Recherche Cancer et Sang, Hôpital Kirchberg, Luxembourg, Luxembourg

    Sebastien Chateauvieux, Fabienne Mack & Marc Diederich

Authors
  1. Emiliano Maiani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudia Di Bartolomeo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesca G Klinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stefano M Cannata
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sergio Bernardini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sebastien Chateauvieux
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fabienne Mack
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maurizio Mattei
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Massimo De Felici
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Marc Diederich
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Gianni Cesareni
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Stefania Gonfloni
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

E.M. did mouse injections, immunohistochemistry, statistical analysis of data and ex vivo bleomycin experiments; C.D.B. helped with in vivo and ex vivo experiments; F.G.K. made ovary fragments and did TUNEL; S.M.C. and S.B. did follicle counting; S.C. did FACS analysis; F.M. did cell culturing; M.M. provided support for in vivo experiments; M.D.F. contributed to scientific discussions; M.D. provides support to complete this study; G.C. provided support and critical reading of the manuscript; S.G. designed the study, set up the immunohistochemistry-based approach, supervised the project and wrote the manuscript.

Corresponding author

Correspondence to Stefania Gonfloni.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–6 and Supplementary Methods (PDF 2845 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maiani, E., Di Bartolomeo, C., Klinger, F. et al. Reply to: Cisplatin-induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib. Nat Med 18, 1172–1174 (2012). https://doi.org/10.1038/nm.2852

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.2852

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing